{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "MISS",
      "answer": "pred ~$1.78 vs. cons $1.82",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.70B vs. cons $1.72B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth excluding contingents",
      "prediction": "MISS",
      "answer": "pred ~-0.5% vs. cons 0.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 contingent-commission outlook",
      "prediction": "BETTER",
      "answer": "guide ~$285M vs. cons $280M (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Second-half organic-growth trajectory",
      "prediction": "LOWER",
      "answer": "guide ~1.8% vs. cons 2.2% (2H 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Accession EBITDA synergy delivery",
      "prediction": "UNCHANGED",
      "answer": "guide ~$35M vs. cons $35M (FY2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -4.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -6.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Underlying organic growth and margin performance imply FY2026/FY2027 EPS revisions of roughly -3.0% versus a pre-report revision baseline of 0.0%, outweighing a modest contingent-commission outlook lift.",
  "day5_confidence": "MEDIUM"
}